Ovarian Cancer Prognosis In Stage Iiic

Ovarian Cancer Prognosis In Stage Iiic

At the moment For diagnosis and first treatment, ovarian cancer is located in a stage based on the size of the tumor, the involvement of lymph nodes and the spread to other parts of the body beyond the nodules. Phase IIIC of ovarian cancer is a tumor of any size that has spread to the lymph nodes near the ovary or has produced cancerous implants in the lining of the abdominal cavity greater than 2 cm in diameter. According to the American Cancer Society, those in stage IIIC have a 35% chance of living 5 years after diagnosis. This statistic includes all women regardless of other factors or types of treatment.

The effect of the location

Although the IIIC stage designation does not distinguish between them, women who metastasize only to the lymph nodes seem to have a higher survival rate than those who have metastases to the cover of the abdominal cavity. In the December 2008 issue of "The Journal of Gynecologic Oncology," the researchers reported a 5-year survival without disease in approximately 65% โ€‹โ€‹of women with nodal metastases alone. Women with metastases to the abdominal cavity had a 5-year disease-free survival of 15 to 20%. Other researchers have reported similar findings.

The effect of tumor grade, obesity, reproductive factors and genes

Under the microscope, each cancer is roughly similar to the normal tissue from which it arises. Pathologists classify those that are less normal in appearance as "poorly differentiated." As reported in May 2008 in "The International Journal of Cancer," women with poorly differentiated cancer are 25% less likely to have a 10-year survival than women with well-differentiated cancer. Obesity at 18 years was a risk factor for a higher death rate, but the use of contraceptives, the age of delivery, the age of first menstruation and the age of menopause had no adverse effects on survival. Ovarian cancer are not all similar at the genetic level, and those differences can affect the response to therapy and survival. An example is the gene that produces a protein called CD70. A research published in 2013 in "OncoTargets and Therapy" established that hyperactivity of this gene caused a lower response in patients to the drug cisplatin, which is the most effective chemotherapy for ovarian cancer.

The effect of age and treatment

According to research published by the American Society of Clinical Oncology, women older than 65 receive the optimal combination of surgery and chemotherapy less often than younger women.The resulting mortality rate for older women is worse, but it can be improved by individualizing treatment according to each woman's health status and the ability to tolerate that treatment.

Optimal treatment for stage IIIC ovarian cancer

According to the National Comprehensive Cancer Network Guidelines, women with stage IIIC disease should undergo surgery to remove the ovaries, uterus, lymph nodes in the pelvis, nodules lymphatics around the main blood vessels, all the visible cancerous implants and the fatty membrane that covers the intestines called omentum. Surgery should be combined with chemotherapy administered directly into the abdominal cavity and continue with chemotherapy given intravenously for 6 to 8 months. As reported in 2013 in "PLos One", patients receiving complete treatment have a survival without disease of 20 to 24 months on average. Those who receive chemotherapy without surgery are disease-free and live for an average of only 8 months.

Video Tutorial: Types, Stages, and Survival Rates of Ovarian Cancer.

Like This? Share With Friends: